338 related articles for article (PubMed ID: 14758572)
21. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and management of medullary thyroid carcinoma.
Massoll N; Mazzaferri EL
Clin Lab Med; 2004 Mar; 24(1):49-83. PubMed ID: 15157557
[TBL] [Abstract][Full Text] [Related]
23. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer.
Colombo C; Verga U; Mian C; Ferrero S; Perrino M; Vicentini L; Dazzi D; Opocher G; Pelizzo MR; Beck-Peccoz P; Fugazzola L
J Clin Endocrinol Metab; 2012 Mar; 97(3):905-13. PubMed ID: 22170709
[TBL] [Abstract][Full Text] [Related]
24. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease.
Rink T; Truong PN; Schroth HJ; Diener J; Zimny M; Grünwald F
Thyroid; 2009 Apr; 19(4):327-32. PubMed ID: 19355822
[TBL] [Abstract][Full Text] [Related]
25. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.
Papi G; Corsello SM; Cioni K; Pizzini AM; Corrado S; Carapezzi C; Fadda G; Baldini A; Carani C; Pontecorvi A; Roti E
J Endocrinol Invest; 2006 May; 29(5):427-37. PubMed ID: 16794366
[TBL] [Abstract][Full Text] [Related]
26. Medullary thyroid carcinoma.
Leboulleux S; Baudin E; Travagli JP; Schlumberger M
Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
[TBL] [Abstract][Full Text] [Related]
27. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.
Vierhapper H; Niederle B; Bieglmayer C; Kaserer K; Baumgartner-Parzer S
Thyroid; 2005 Nov; 15(11):1267-72. PubMed ID: 16356091
[TBL] [Abstract][Full Text] [Related]
28. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects.
Karanikas G; Moameni A; Poetzi C; Zettinig G; Kaserer K; Bieglmayer C; Niederle B; Dudczak R; Pirich C
J Clin Endocrinol Metab; 2004 Feb; 89(2):515-9. PubMed ID: 14764755
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter.
Ozgen AG; Hamulu F; Bayraktar F; Yilmaz C; Tüzün M; Yetkin E; Tunçyürek M; Kabalak T
Thyroid; 1999 Jun; 9(6):579-82. PubMed ID: 10411120
[TBL] [Abstract][Full Text] [Related]
30. Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies.
Kim JM; Chung KW; Kim SW; Choi SH; Min HS; Kim JN; Won WJ; Kim SK; Lee JI; Chung JH; Kim SW
Head Neck; 2010 Jan; 32(1):68-75. PubMed ID: 19536770
[TBL] [Abstract][Full Text] [Related]
31. PDN-21 (katacalcin) and chromogranin A: tumor markers for medullary thyroid carcinoma.
Raue F; Blind E; Grauer A
Henry Ford Hosp Med J; 1992; 40(3-4):296-8. PubMed ID: 1483876
[TBL] [Abstract][Full Text] [Related]
32. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients.
Chambon G; Alovisetti C; Idoux-Louche C; Reynaud C; Rodier M; Guedj AM; Chapuis H; Lallemant JG; Lallemant B
J Clin Endocrinol Metab; 2011 Jan; 96(1):75-81. PubMed ID: 20881258
[TBL] [Abstract][Full Text] [Related]
33. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
Elisei R; Bottici V; Luchetti F; Di Coscio G; Romei C; Grasso L; Miccoli P; Iacconi P; Basolo F; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2004 Jan; 89(1):163-8. PubMed ID: 14715844
[TBL] [Abstract][Full Text] [Related]
34. Sensitive calcitonin measurement by two-site immunometric assays: implications for calcitonin screening in nodular thyroid disease.
Saller B; Görges R; Reinhardt W; Haupt K; Janssen OE; Mann K
Clin Lab; 2002; 48(3-4):191-200. PubMed ID: 11934221
[TBL] [Abstract][Full Text] [Related]
35. Incidental medullary thyroid microcarcinoma revealed by mild increase of preoperative serum calcitonin levels: therapeutic implications.
Boschin IM; Torresan F; Toniato A; Zane M; Ide EC; Pennelli G; Rampin L; Colletti PM; Rubello D; Pelizzo MR
Endocrine; 2014 Apr; 45(3):448-53. PubMed ID: 23884895
[TBL] [Abstract][Full Text] [Related]
36. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada.
Daniels GH
Thyroid; 2011 Nov; 21(11):1199-207. PubMed ID: 21936671
[TBL] [Abstract][Full Text] [Related]
37. Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or c-cell hyperplasia.
Borchhardt KA; Heinzl H; Gessl A; Hörl WH; Kaserer K; Sunder-Plassmann G
Kidney Int; 2006 Dec; 70(11):2014-20. PubMed ID: 17051143
[TBL] [Abstract][Full Text] [Related]
38. Medullary thyroid carcinoma and hormones.
Cohen R; Quidville V; Bihan H
Ann Med Interne (Paris); 2003 Mar; 154(2):109-16. PubMed ID: 12746649
[TBL] [Abstract][Full Text] [Related]
39. Routine measurement of plasma calcitonin in nodular thyroid diseases.
Vierhapper H; Raber W; Bieglmayer C; Kaserer K; Weinhäusl A; Niederle B
J Clin Endocrinol Metab; 1997 May; 82(5):1589-93. PubMed ID: 9141554
[TBL] [Abstract][Full Text] [Related]
40. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?
Pina G; Dubois S; Murat A; Berger N; Niccoli P; Peix JL; Cohen R; Guillausseau C; Charrie A; Chabre O; Cornu C; Borson-Chazot F; Rohmer V;
Clin Endocrinol (Oxf); 2013 Mar; 78(3):358-64. PubMed ID: 22913268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
